Výsledky vyhledávání

Akademický článek

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population

Autor: J. Maksimenko, A. Irmejs, G. Trofimovičs, D. Bērziņa, E. Skuja, G. Purkalne, E. Miklaševičs, J. Gardovskis

Publikováno v: Hereditary Cancer in Clinical Practice, Vol 16, Iss 1, Pp 1-7 (2018)

Abstract Background Pathogenic BRCA1 founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% of all consecutive primary breast cancers and 9.9% of all consecutive primary ovarian cancers. Identifying germline pathogenic gene variants in patien

Externí odkaz: https://doaj.org/article/860d89ac87074c95859c4153b0c9d9c4

Zobrazit plný text záznamu

Author response for 'Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumours and differentiation from small intestinal neuroendocrine tumours'

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d9be146367a673fd30681b02784de84
https://doi.org/10.1111/jne.13176/v2/response1

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

OA03.08 Trilaciclib Reduces the Need for Growth Factors and Red Blood Cell Transfusions to Manage Chemotherapy-Induced Myelosuppression

Autor: G. Purkalne, R. Ferrarotto, I. Anderson, B. Medgyasszay, M.R. García-Campelo, W. Edenfield, T. Feinstein, J. Johnson, S. Kalmadi, P. Lammers, A.S. Hernandez, Y. Pritchett, R.K. Malik, S.R. Morris, T. Csőszi

Publikováno v: Journal of Thoracic Oncology. 16:S4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cbbcce3064d979e104c927381e68ca9
https://doi.org/10.1016/j.jtho.2020.10.026

Zobrazit plný text záznamu

High frequency of pathogenic non-founder germline mutations in

Autor: J, Maksimenko, A, Irmejs, G, Trofimovičs, D, Bērziņa, E, Skuja, G, Purkalne, E, Miklaševičs, J, Gardovskis

Publikováno v: Hereditary cancer in clinical practice. 16

PathogenicFifteen female probands and 1 male proband that met National Comprehensive Cancer Network (NCCN) criteria forIn 44% (7 out of 16) of tested probands, pathogenic mutations were identified. Six probands carried pathogenic mutations inA relati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::909876d92a1689f10d5a5cabc5f4a856
https://pubmed.ncbi.nlm.nih.gov/29928469

Zobrazit plný text záznamu

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Autor: S. Ramalingam, J. Crawford, A. Chang, C. Manegold, R. Perez-Soler, J.-Y. Douillard, N. Thatcher, F. Barlesi, T. Owonikoko, Y. Wang, P. Pultar, J. Zhu, R. Malik, G. Giaccone, S. Della-Fiorentina, S. Begbie, R. Jennens, J. Dass, K. Pittman, N. Ivanova, T. Koynova, P. Petrov, A. Tomova, V. Tzekova, F. Couture, V. Hirsh, R. Burkes, R. Sangha, M. Ambrus, T. Janaskova, J. Musil, J. Novotny, P. Zatloukal, J. Jakesova, K. Klenha, J. Roubec, J. Vanasek, J. Fayette, J. Bennouna-Louridi, C. Chouaid, J. Mazières, H. Vallerand, G. Robinet, P.-J. Souquet, D. Spaeth, R. Schott, H. Lena, Y. Martinet, C. El Kouri, N. Baize, A. Scherpereel, O. Molinier, F. Fuchs, K.M. Josten, N. Marschner, F. Schneller, T. Overbeck, M. Thomas, J. von Pawel, M. Reck, W. Schuette, V. Hagen, C.-P. Schneider, V. Georgoulias, I. Varthalitis, K. Zarogoulidis, K. Syrigos, C. Papandreou, C. Bocskei, E. Csanky, E. Juhasz, G. Losonczy, Z. Mark, I. Molnar, Z. Papai-Szekely, S. Tehenes, I. Vinkler, S. Almel, A. Bakshi, S. Bondarde, A. Maru, A. Pathak, R.M. Pedapenki, K. Prasad, S.V.S.S. Prasad, N. Kilara, D. Gorijavolu, C.D. Deshmukh, S. John, L.M. Sharma, D. Amoroso, E. Bajetta, P. Bidoli, A. Bonetti, F. De Marinis, M. Maio, R. Passalacqua, S. Cascinu, A. Bearz, M. Bitina, A. Brize, G. Purkalne, M. Skrodele, A.A. Baba, K. Ratnavelu, M.H. Saw, M.C. Samson-Fernando, G.E. Ladrera, J. Jassem, P. Koralewski, P. Serwatowski, M. Krzakowski, C. Cebotaru, D. Filip, D.E. Ganea-Motan, C.H. Ianuli, I.G. Manolescu, A. Udrea, O. Burdaeva, M. Byakhov, A. Filippov, S. Lazarev, I. Mosin, S. Orlov, D. Udovitsa, A. Khorinko, S. Protsenko, H.L. Lim, Y.O. Tan, E.H. Tan, R. Bastus Piulats, J. Garcia-Foncillas, J. Valdivia, J. de Castro, M. Domine Gomez, S.W. Kim, J.-S. Lee, H.K. Kim, J.S. Lee, S.W. Shin, D.-W. Kim, Y.-C. Kim, K.C. Park, C.-S. Chang, G.-C. Chang, Y.-G. Goan, W.-C. Su, C.-M. Tsai, H.-P. Kuo, M. Benekli, G. Demir, E. Gokmen, A. Sevinc, M. Haigentz, M. Agarwal, S. Pandit, R. Araujo, N. Vrindavanam, P. Bonomi, A. Berg, J. Wade, R. Bloom, B. Amin, R. Camidge, D. Hill, M. Rarick, P. Flynn, L. Klein, K. Lo Russo, M. Neubauer, P. Richards, R. Ruxer, M. Savin, D. Weckstein, R. Rosenberg, T. Whittaker, D. Richards, W. Berry, C. Ottensmeier, A. Dangoor, N. Steele, Y. Summers, E. Rankin, K. Rowley, S. Giridharan, H. Kristeleit, C. Humber, P. Taylor

Publikováno v: Annals of Oncology. 24:2875-2880

Background Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC). Patients and methods An FORTIS-M trial was an internat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279f128904fe8fc09b31972c2bf65519
https://doi.org/10.1093/annonc/mdt371

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání